Lokken Investment Group LLC Buys New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Lokken Investment Group LLC acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 14,299 shares of the biopharmaceutical company's stock, valued at approximately $347,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $27,000. Charles Schwab Investment Management Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company's stock valued at $26,023,000 after buying an additional 79,182 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $339,000. Raymond James Financial Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $6,887,000. Finally, Amundi increased its position in shares of Catalyst Pharmaceuticals by 188.2% during the fourth quarter. Amundi now owns 56,609 shares of the biopharmaceutical company's stock valued at $1,291,000 after buying an additional 36,968 shares during the period. 79.22% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $32.83.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the sale, the insider owned 68,873 shares of the company's stock, valued at $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the sale, the insider directly owned 41,081 shares of the company's stock, valued at approximately $1,085,360.02. This trade represents a 3.75% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Trading Up 1.3%

Shares of NASDAQ CPRX traded up $0.27 during midday trading on Thursday, hitting $21.45. 1,411,719 shares of the company's stock were exchanged, compared to its average volume of 1,141,437. Catalyst Pharmaceuticals, Inc. has a 12-month low of $15.34 and a 12-month high of $26.58. The company has a market cap of $2.62 billion, a price-to-earnings ratio of 13.66, a PEG ratio of 0.86 and a beta of 0.66. The business's fifty day moving average price is $23.28 and its two-hundred day moving average price is $22.88.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.